Target intelligence / Profile preview

Human Immunodeficiency Virus Group-Specific Antigen Protein (Gag)

Target
Gag
Molecular classification
Structural protein, Viral protein, Polyprotein
01

Overview

The group-specific antigen protein, commonly referred to as Gag, is a polyprotein encoded by the gag gene of the human immunodeficiency virus (HIV). It is a major structural protein essential for HIV virion assembly, maturation, and infectivity. Gag orchestrates multiple steps in the late phase of the viral lifecycle, including genomic RNA encapsidation, particle formation via multimerization, and interactions with both viral and host cellular proteins. It is initially synthesized as a 55 kDa precursor protein (p55), which is then cleaved by the viral protease into several mature structural proteins: Matrix (MA/p17), Capsid (CA/p24), Nucleocapsid (NC/p7), p6, and Spacer Peptides (SP1 & SP2). Failure of this cleavage results in non-infectious virions. Antibodies against Gag-derived proteins (especially p24) are widely used as diagnostic markers for early HIV infection. Disruption or inhibition of Gag processing/maturation forms the basis for some antiretroviral drug strategies.

Other names
Group-specific antigenGag polyproteinp55 precursorPr55Gag
02

Mechanism of action

Inhibition of Gag processing/maturation, leading to production of non-infectious virions.

03

Biological functions

Virion assemblyGenomic RNA encapsidationParticle formationMembrane targetingCore/capsid formationGenomic RNA binding/packagingVirus releaseMultimerization
04

Disease associations

InfectionHIV infectionAIDS
05

Safety considerations

Drug resistanceOff-target effects of drugs targeting Gag
06

Biomarkers

p24 antibodies (for HIV infection diagnosis)

Beyond the preview

Go deeper on Human Immunodeficiency Virus Group-Specific Antigen Protein (Gag).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human Immunodeficiency Virus Group-Specific Antigen Protein (Gag).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call